Cargando…
Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome
In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061238/ https://www.ncbi.nlm.nih.gov/pubmed/29948970 http://dx.doi.org/10.1007/s12672-018-0335-8 |
_version_ | 1783342180629217280 |
---|---|
author | Chen, Zongping Deng, Jichun Yan, Yong Li, Min Chen, Chanjuan Chen, Chao Zhao, Sicong Song, Tao Liu, Tong Wen, Xin Yao, Yuhong |
author_facet | Chen, Zongping Deng, Jichun Yan, Yong Li, Min Chen, Chanjuan Chen, Chao Zhao, Sicong Song, Tao Liu, Tong Wen, Xin Yao, Yuhong |
author_sort | Chen, Zongping |
collection | PubMed |
description | In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment to evaluate the effects of various treatment methods on MetS. We analyzed data of 1162 PCa patients, whether or not diagnosed with MetS, and changes in MetS patients after PCa treatment. Data of lower urinary tract symptoms, C-reactive protein (CRP), platelet distribution width (PDW), prostate-specific antigen (PSA), Gleason score, clinical stage, treatment methods, and progressive incidents were evaluated using logistic regression according to MetS diagnosis. The results showed significant differences in the prevalence of MetS before (17.38%) and after (23.67%) PCa treatment (P < 0.001). Bad diet, living habits, and prostate cancer treatment were considered as risk factors for MetS (OR = 1.731, 95%CI 1.367–2.193, P < 0.001). Radical prostatectomy (RP), androgen deprivation therapy including surgical castration and medical castration, iodine-125 seed brachytherapy ((125)I limited), and chemotherapy were independent risk factors of MetS. The MetS incidence rates after treatment in ADT+(125)I limited+chemotherapy compared to RP+TURP+EBRT were statistically significant at the corresponding risk grade (all P < 0.001). After treatment, the occurrence rates of progressive incidences were higher in MetS-PCa patients compared to non-MetS-PCa patients (all P < 0.001). So, the findings suggested that among PCa patients, multiple factors contribute to the occurrence of MetS, and PCa treatment is one among them. ADT+(125)I limited+chemotherapy may be the most influential treatment for MetS. |
format | Online Article Text |
id | pubmed-6061238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-60612382018-08-09 Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome Chen, Zongping Deng, Jichun Yan, Yong Li, Min Chen, Chanjuan Chen, Chao Zhao, Sicong Song, Tao Liu, Tong Wen, Xin Yao, Yuhong Horm Cancer Original Paper In clinical practice, few prostate cancer (PCa) patients are associated with metabolic syndrome (MetS), while few others acquire MetS during treatment. Whether the treatment of PCa increases the occurrence of MetS remains to be confirmed. This study reviewed the changes in MetS patients before and after PCa treatment to evaluate the effects of various treatment methods on MetS. We analyzed data of 1162 PCa patients, whether or not diagnosed with MetS, and changes in MetS patients after PCa treatment. Data of lower urinary tract symptoms, C-reactive protein (CRP), platelet distribution width (PDW), prostate-specific antigen (PSA), Gleason score, clinical stage, treatment methods, and progressive incidents were evaluated using logistic regression according to MetS diagnosis. The results showed significant differences in the prevalence of MetS before (17.38%) and after (23.67%) PCa treatment (P < 0.001). Bad diet, living habits, and prostate cancer treatment were considered as risk factors for MetS (OR = 1.731, 95%CI 1.367–2.193, P < 0.001). Radical prostatectomy (RP), androgen deprivation therapy including surgical castration and medical castration, iodine-125 seed brachytherapy ((125)I limited), and chemotherapy were independent risk factors of MetS. The MetS incidence rates after treatment in ADT+(125)I limited+chemotherapy compared to RP+TURP+EBRT were statistically significant at the corresponding risk grade (all P < 0.001). After treatment, the occurrence rates of progressive incidences were higher in MetS-PCa patients compared to non-MetS-PCa patients (all P < 0.001). So, the findings suggested that among PCa patients, multiple factors contribute to the occurrence of MetS, and PCa treatment is one among them. ADT+(125)I limited+chemotherapy may be the most influential treatment for MetS. Springer US 2018-06-09 /pmc/articles/PMC6061238/ /pubmed/29948970 http://dx.doi.org/10.1007/s12672-018-0335-8 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Chen, Zongping Deng, Jichun Yan, Yong Li, Min Chen, Chanjuan Chen, Chao Zhao, Sicong Song, Tao Liu, Tong Wen, Xin Yao, Yuhong Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title | Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title_full | Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title_fullStr | Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title_full_unstemmed | Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title_short | Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome |
title_sort | risk analysis of prostate cancer treatments in promoting metabolic syndrome development and the influence of increased metabolic syndrome on prostate cancer therapeutic outcome |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061238/ https://www.ncbi.nlm.nih.gov/pubmed/29948970 http://dx.doi.org/10.1007/s12672-018-0335-8 |
work_keys_str_mv | AT chenzongping riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT dengjichun riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT yanyong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT limin riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT chenchanjuan riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT chenchao riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT zhaosicong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT songtao riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT liutong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT wenxin riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome AT yaoyuhong riskanalysisofprostatecancertreatmentsinpromotingmetabolicsyndromedevelopmentandtheinfluenceofincreasedmetabolicsyndromeonprostatecancertherapeuticoutcome |